bi 3720931
Gene therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 11, 2024 (NCT06515002)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cystic fibrosis transmembrane conductance regulatorSupplementation
CFTR supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06962852 | Phase 1/Phase 2 (Phase 2) | May 20, 2025 | Boehringer Ingelheim |
| NCT06515002 | Phase 1/Phase 2 (Phase 2) | Sep 11, 2024 | Boehringer Ingelheim |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 2 | 2 | 1 | 2024 |
1 organizations
Page 1 / 1